883 Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Author(s): Alexey Danilov, MD, PhD et al.

Published: 9 December 2024

Copyright: © 2024 The Authors. All rights reserved. Officially licensed by ASH.

Download valid until December 31, 2025

By accessing this content you are agreeing to the following terms and conditions, and certifying that the content provided is for your personal use only.

  • The modification, adaptation, manipulation, transformation, translation or creation of derivative works based on the materials is prohibited
  • The user may not remove, obscure or modify any copyright or other notices or disclaimers included in the materials
  • The user may not transmit in any format the materials to other persons
  • Printing copies for distribution for any reason is strictly prohibited
  • The user will take all reasonable security measures necessary to prevent unauthorised duplication or unauthorised distribution of the materials
  • You accept Springer Healthcare’s Privacy Policy
Voucher code (required)
Your Name (required)
Your Email (required)
 

Disclaimer

This content is provided with support from Eli-Lilly.

Reused with permission from the American Society of Hematology. © 2024 The Authors. All rights reserved. Officially licensed by ASH.

This content is provided for informational purposes and personal use only, and is not intended to provide medical advice, diagnosis, or treatment or for commercial use. The ideas and opinions expressed herein do not necessarily reflect those of the American Society of Hematology (ASH®). The mention of any product, service or therapy in this collection of materials should not be construed as an endorsement of the products mentioned.